Wird geladen...
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient
Sorafenib, a multitargeted tyrosine kinase inhibitor, has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC). As the clinical use of sorafenib increases, many adverse effects have been reported, such as hand-foot skin reaction, diarrhea, anorexia, asthenia, alope...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Baishideng Publishing Group Co., Limited
2011
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3020384/ https://ncbi.nlm.nih.gov/pubmed/21246003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v17.i2.267 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|